CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record.

A new mouse mutant for the LDL receptor identified using ENU mutagenesis

Svenson, Karen L., Ahituv, Nadav, Durgin, Rebecca S., Savage, Holly, Magnani, Phyllis A., Foreman, Oded, Paigen, Beverly, Peters, Luanne L.·2008·Journal of Lipid Research
DOI 10.1194/jlr.m800303-jlr200
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m800303-jlr200

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The WHC modification was found to trap LDLR in the ER, preventing glycosylation in the Golgi apparatus and resulting in protein degradation rather than trafficking to the cell surface.

    “This modification was found to trap LDLR in the ER, preventing glycosylation in the Golgi apparatus, and resulting in protein degradation rather than trafficking to the cell surface89–91.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [89]

    The Discussion (p. 2459) predicts that the WHC mutation prevents LDLR transport from the endoplasmic reticulum to the Golgi and cell surface; it does not report this as an observed finding. The passage does not establish that Golgi glycosylation is prevented or that the protein is degraded. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • ENU mutagenesis generated the Wicked High Cholesterol (WHC) mouse model, which developed hypercholesterolemia at levels found in LDLR knockout animals.

    “To model these Class II mutations ENU mutagenesis generated a mouse model, the Wicked High Cholesterol (WHC) mouse89, that developed hypercholesterolemia at levels found in LDLR knockout animals.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [89]

    The Abstract identifies WHC as an LDL receptor mutation found through ENU mutagenesis. In “Comparison of WHC homozygotes to Ldlr KO strain” (page not provided), the paper reports similar cholesterol levels on chow, but significantly higher total cholesterol in knockout mice after an atherogenic diet. The unqualified claim that WHC reached knockout cholesterol levels omits that diet-dependent difference. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 32

  1. Piedrahita, 1992, Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells, Proc. Natl. Acad. Sci. USA., 89, 4471, 10.1073/pnas.89.10.4471 · DOI · Paper page
  2. Ishibashi, 1993, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery, J. Clin. Invest., 92, 883, 10.1172/JCI116663 · DOI · Paper page
  3. Warden, 1993, Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II, Science., 261, 469, 10.1126/science.8332912 · DOI
  4. Farese, 1996, Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100, Proc. Natl. Acad. Sci. USA., 93, 6393, 10.1073/pnas.93.13.6393 · DOI
  5. Leppanen, 1998, Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice, Atherosclerosis., 136, 147, 10.1016/S0021-9150(97)00196-2 · DOI
  6. Miyake, 2002, Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice, Arterioscler. Thromb. Vasc. Biol., 22, 121, 10.1161/hq0102.102588 · DOI
  7. Hardisty, 2003, The deaf mouse mutant Jeff (Jf) is a single gene model of otitis media, J. Assoc. Res. Otolaryngol., 4, 130, 10.1007/s10162-002-3015-9 · DOI
  8. Ahituv, 2004, An ENU-induced mutation in AP-2alpha leads to middle ear and ocular defects in Doarad mice, Mamm. Genome., 15, 424, 10.1007/s00335-004-2334-z · DOI
  9. Toye, 2004, A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene, Diabetes., 53, 1577, 10.2337/diabetes.53.6.1577 · DOI
  10. Yu, 2004, ENU induced mutations causing congenital cardiovascular anomalies, Development., 131, 6211, 10.1242/dev.01543 · DOI
  11. Feng, 2007, Functional deficiency in IL-7 caused by an N-ethyl-N-nitrosourea-induced point mutation, Genetics., 175, 545, 10.1534/genetics.106.066043 · DOI
  12. Svenson, 2003, Identifying new mouse models of cardiovascular disease: a review of high-throughput screens of mutagenized and inbred strains, J. Appl. Physiol., 94, 1650, 10.1152/japplphysiol.01029.2003 · DOI
  13. Justice, 2000, Effects of ENU dosage on mouse strains, Mamm. Genome., 11, 484, 10.1007/s003350010094 · DOI
  14. Weber, 2000, Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains, Genesis., 26, 230, 10.1002/(SICI)1526-968X(200004)26:4<230::AID-GENE20>3.0.CO;2-S · DOI
  15. Nishina, 1993, Atherosclerosis and plasma and liver lipids in nine inbred strains of mice, Lipids., 28, 599, 10.1007/BF02536053 · DOI
  16. Taylor, 1996, Detection of obesity QTLs on mouse chromosomes 1 and 7 by selective DNA pooling, Genomics., 34, 389, 10.1006/geno.1996.0302 · DOI
  17. Paigen, 1987, Quantitative assessment of atherosclerotic lesions in mice, Atherosclerosis., 68, 231, 10.1016/0021-9150(87)90202-4 · DOI
  18. Svenson, 2007, Multiple trait measurements in 43 inbred mouse strains capture the phenotypic diversity characteristic of human populations, J. Appl. Physiol., 102, 2369, 10.1152/japplphysiol.01077.2006 · DOI
  19. Lusis, 2007, The problem of passenger genes in transgenic mice, Arterioscler. Thromb. Vasc. Biol., 27, 2100, 10.1161/ATVBAHA.107.147918 · DOI
  20. Srivastava, 1991, Expression of LDL receptor, apolipoprotein B, apolipoprotein A-I and apolipoprotein A-IV mRNA in various mouse organs as determined by a novel RNA-excess solution hybridization assay, Biochim. Biophys. Acta., 1090, 95, 10.1016/0167-4781(91)90042-K · DOI
  21. Hobbs, 1990, The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein, Annu. Rev. Genet., 24, 133, 10.1146/annurev.ge.24.120190.001025 · DOI · Paper page
  22. Schmidt, 2000, Familial hypercholesterolemia in Austria reflects the multi-ethnic origin of our country, Atherosclerosis., 148, 431, 10.1016/S0021-9150(99)00469-4 · DOI
  23. Salazar, 2002, Molecular basis of familial hypercholesterolemia in Brazil: identification of seven novel LDLR gene mutations, Hum. Mutat., 19, 462, 10.1002/humu.9032 · DOI
  24. Mozas, 2004, Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR, Hum. Mutat., 24, 187, 10.1002/humu.9264 · DOI
  25. Vitaterna, 1994, Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior, Science., 264, 719, 10.1126/science.8171325 · DOI · Paper page
  26. Inoue, 2004, A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program, Hum. Mol. Genet., 13, 1147, 10.1093/hmg/ddh133 · DOI
  27. Mohr, 2004, Hypercholesterolemia in ENU-induced mouse mutants, J. Lipid Res., 45, 2132, 10.1194/jlr.M400236-JLR200 · DOI
  28. Kermany, 2006, Identification of 17 hearing impaired mouse strains in the TMGC ENU-mutagenesis screen, Hear. Res., 220, 76, 10.1016/j.heares.2006.07.011 · DOI
  29. Keays, 2007, Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans, Cell., 128, 45, 10.1016/j.cell.2006.12.017 · DOI
  30. Cook, 2007, Neurobehavioral mutants identified in an ENU-mutagenesis project, Mamm. Genome., 18, 559, 10.1007/s00335-007-9035-3 · DOI
  31. Davies, 2008, A missense mutation in the murine Opa3 gene models human Costeff syndrome, Brain., 131, 368, 10.1093/brain/awm333 · DOI
  32. Aigner, 2008, Diabetes models by screen for hyperglycemia in phenotype-driven ENU mouse mutagenesis projects, Am. J. Physiol. Endocrinol. Metab., 294, E232, 10.1152/ajpendo.00592.2007 · DOI

Cited by

Sorted by citations

Metadata

Authors
Svenson, K. L., Ahituv, N., Durgin, R. S., Savage, H., Magnani, P. A., Foreman, O., Paigen, B., & Peters, L. L.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2008-11
Volume
49
Issue
11
Pages
2452-2462
ISSN
0022-2275
DOI
10.1194/jlr.m800303-jlr200
Cited by
15
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review